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ABSTRACT 
The present study showed that the glucocorticoid/ progesterone antagonists, 17ß-
hydroxy-11ß-(4-dimethylamino-phenyl-1)-17-(prop-1-ynyl)estra-4, 9-dien-3-one 
(RU486) and 17ß-hydroxy-11ß-(4-dimethylamino-phenyl-1)-17-(propan-3-ol)estra-4, 
9-dien-3-one (ZK 98299), inhibit the binding of labeled dihydromorphine to µ-opioid 
receptors present on membrane preparations derived from rat and mouse brain, as well 
as from human neuroblastoma cells. The inhibitory effect of RU486 was dose-
dependent and linked to a decrease of the affinity of labeled dihydromorphine to the µ-
opioid receptors. Kinetic experiments have shown that RU486 induces a decrease of the 
association rate constant (k +1) of dihydromorphine. RU486 also proved able to 
dissociate the dihydromorphine-µ receptor complex, although at a rate slower than that 
exhibited by unlabeled dihydromorphine.  Finally, the addition of NaCl (100 mM) to 
the incubation buffer induced a 50% decrease of the inhibitory effect of RU486. A 6-
day treatment of neuroblastoma cells with RU486 eliminated the inhibitory effect 
morphine exerts on the intracellular accumulation  of cyclic AMP induced by 
prostaglandin E1. These results indicate that RU-486 may interact with brain µ-opioid 
receptors in vitro, by decreasing the affinity of opioid ligands. 
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1. INTRODUCTION 
 
  Evidence is accumulating which indicates that not all the actions of steroid 
hormones are mediated by genomic mechanisms (Celotti et al., 1992; Wehling, 1994). 
The best examples of this are provided by steroid effects occurring in the brain, where 
hormonal steroids modify the electrical activity of neurons (Ramirez et al., 1990; 
Saphier and Feldman, 1988), and induce sleep and/or anaesthesia (Gee et al., 1988; 
Sutanto et al., 1989) with latencies that are too short to imply an effect occurring 
through classical intracellular receptors. These observations suggest the possible 
existence of membrane-linked modes of action of steroid derivatives. In line with this 
hypothesis, direct binding of several steroid hormones has been found to occur in rat 
brain membrane preparations (Ramirez et al., 1990; Towle and Sze, 1983; Wehling, 
1994). Moreover, some 5α-reduced metabolites of progesterone have been reported to 
interact with a specific binding site located on the γ-aminobutyric acid (GABA) type A 
receptor-chloride ionophore complex (Belelli et al., 1990), and to potentiate the actions 
of GABA on the GABAA receptor (Majewska, 1990; Majewska et al., 1986). Finally, 
steroids have been shown to be able to interfere with the binding of some 
neurotransmitters to their physiological receptors; progesterone, in particular, appears 
to modify the binding of specific ligands to the σ (Su et al., 1988) and the muscarinic 
receptors (Klangkalya and Chan, 1988). However, the chemical characteristics of 
steroidal compounds, and specially their hydrophobicity, suggest that the interference 
exerted by steroids on the binding of neurotransmitters to their receptors might result 
from indirect non-specific actions, for instance, influences exerted on the physical 
properties of the membranes anchoring these receptors (Sargent and Schwyzer, 1986). 
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There is a multifaceted interplay between steroid hormones and the brain opioid 
systems. For instance, sex steroids are believed to exert their effects on gonadotropin 
secretion at least in part through the modulation of hypothalamic opioids and/or their 
receptors (Bhanot and Wilkinson, 1984; Gabriel et al., 1983; Kalra, 1993; Limonta et 
al., 1986; Piva et al., 1986; Piva et al., 1985). In particular, it has been reported that, in 
the female rat, physiological as well as pharmacologically induced changes of the 
serum level of sex steroids are accompanied by variations of µ-opioid receptors binding 
characteristics in the whole brain and in the hypothalamus (Casulari et al., 1987; Dondi 
et al., 1992; Jacobson and Kalra, 1989; Maggi et al., 1993; Maggi et al., 1989; Maggi et 
al., 1994; Weiland and Wise, 1990).  
The present work was performed to verify whether steroids might exert some direct 
actions on the binding characteristics of opioid receptors. To this purpose, the influence 
exerted by a number of steroidal compounds on the binding of labeled dihydromorphine 
to µ-opioid receptors was investigated. Membrane preparations obtained from the 
whole brain of adult female rats and adult male mice, as well as from a human 
neuroblastoma cell line (SH-SY5Y, known to be rich in µ-opioid receptors) (Yu et al., 
1986) were used in the present study. Other experiments were performed on living SH-
SY5Y neuroblastoma cells, to analyse whether the treatment with steroidal compounds 
might be followed by alterations of biochemical parameters known to be linked to µ-
opioid receptor function (e.g., inhibition of cyclic AMP accumulation). 
 
2. MATERIALS AND METHODS 
2.1 Animals and cell cultures 
Adult female rats of the Sprague-Dawley strain and male CD1 mice (Charles River, 
Calco, Italy) were used through the experiments. The animals were caged in groups of 
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five, in rooms with controlled temperature and humidity. The light schedule was 14 h 
light-10 h darkness (lights on: 06.30 h). A standard pellet diet and water were available 
ad libitum.  The animals were killed at 10.00 h in the morning by cervical dislocation 
and the brains  were rapidly removed from the skulls and processed for membrane 
preparation. 
SH-SY5Y cells (kindly provided by Dr. June Biedler, Sloan-Kettering Memorial 
Cancer Centre, New York) were grown in monolayer at 37°C in a humidified CO2 
incubator. The culture medium was Minimum Essential Medium containing non-
essential aminoacids, 1 mM sodium pyruvate, 100 µg/ml streptomycin, 100 UI/ml 
penicillin, 10 mg/l of phenol red (Biochrom KG, Berlin, Germany) and supplemented 
with 10% fetal calf serum (Gibco, Grand Island, NY, USA). For the treatments, a 
thousand fold concentrated stock solution of RU486 in 70% dimethylsulfoxide 
(DMSO) was diluted in the culture medium to a final concentration of 10 µM of the 
steroid. The culture medium was replaced at 2-day intervals. Subconfluent cells were 
then washed twice and harvested in Dulbecco's phosphate buffered saline solution, 
without calcium and magnesium salts, and containing 0.4% EDTA (Biochrom KG, 
Berlin, Germany), then collected by centrifugation and processed for membrane 
preparation.  
2.2 Membrane preparations 
Animal brains and neuroblastoma cells were individually homogenised (glass-teflon 
homogeniser) in 10 volumes of sucrose 0.32 M. Homogenates were centrifuged at 
1,400 x g for 10 min; the resulting supernatants were decanted and preincubated for 30 
min at 37°C, to eliminate the endogenous ligand that might interfere with the assay of 
the µ-opioid binding sites. At the end of the incubation, the material was further 
centrifuged at 48,000 x g for 30 min.  The pellets obtained (membrane preparations) 
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were resuspended and homogenised in 3 volumes of assay buffer (Tris-HCl 50 mM, pH 
7.4) and stored at -70°C until the time of the binding assay. In previous experiments, no 
loss of µ-opioid binding sites was observed up to 15-day storage at -70°C. The protein 
content of each plasma membrane preparation was determined by a micro method 
(Bradford, 1976) using human serum albumin as standard.  
2.3 Chemicals 
17ß-hydroxy-11ß-(4-dimethylamino-phenyl-1)-17-(prop-1-ynyl)estra-4, 9-dien-3-one 
(RU486) was kindly provided by Roussel UCLAF (F); 17ß-hydroxy-11ß-(4-
dimethylamino-phenyl-1)-17-(propan-3-ol)estra-4, 9-dien-3-one (ZK 98299) was 
provided by Schering (Berlin, Germany); (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-
N,N-dimethyl-ethanamine citrate (tamoxifen) was a generous gift of Zeneca (Milano, 
Italy). Other compounds of high chemical purity were obtained from commercial 
sources (Sigma Chemicals, St. Louis, MA; Merck, Darmstadt, Germany) 
[3H]dihydromorphine (87 Ci/mmol), [3H][D-Ala2, N-Me-Phe4, Gly5-ol]enkephalin 
([3H]DAGO, 55 Ci/mmol) and [3H]diprenorphine (31 Ci/mmol) were purchased from 
NEN-Dupont de Nemours (Florence, Italy).  
2.4 Receptor binding assay 
[3H]dihydromorphine was chosen as the ligand for binding experiments since this drug, 
at the doses required for the assay, binds specifically to the µ-opioid receptors (Pfeiffer 
and Herz, 1982). 
The conditions of the receptor binding assay were optimised as previously described 
(Maggi et al., 1993). Aliquots from a pool of tissue membrane preparations (200 µg of 
protein) were incubated in the presence of labeled ligands (1 nM for single point and 
kinetic experiments and from 0.1 to 100 nM for saturation curves). Incubations were 
carried out at 25°C for 30 min. The content of the tubes was then individually filtered 
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through Whatman GF/B filters pre-soaked in assay buffer saturated with isoamyl 
alcohol; each filter was washed twice with 5 ml ice-cold assay buffer and counted in 7 
ml Instagel scintillation cocktail (Packard Instruments, Milano). All the samples were 
assayed in duplicate. In order to minimise inter-assay variation, different groups of 
experiments were performed in the same assay. 
2.5 cyclic AMP assay  
Intracellular cyclic AMP accumulation was measured in subconfluent SH-SY5Y cells 
over a 15-min incubation period at 37°C in the presence of 1 µM of prostaglandin E1 
(Sigma Chemicals), as activator of adenylyl cyclase, after a 10-min preincubation with 
the phosphodiesterase inhibitor, 3-isobutyl-1-methyl-xanthine (0.5 mM) (Sigma 
Chemicals). A commercial binding protein assay kit (Amersham, Milano, Italy) was 
used to evaluate cyclic AMP concentration in ethanol-extracted cells according to the 
manufacturers' instructions.  
2.6 Statistical analysis  
Comparisons of the competing effects of steroids were statistically evaluated by 
analysis of variance (ANOVA) using the SYSTAT program. The competition curves 
were analysed by means of a Macintosh version of the ALLFIT program (De Lean et 
al., 1978) kindly provided by Dr. V.Guardabasso (Cyanamid, Catania, Italy). The 
saturation curves were analysed by means of the LIGAND program (Munson and 
Rodbard, 1980) adapted for a Macintosh computer by Dr. G.E. Rovati (Inst. Pharmacol. 
Sciences, Milano, Italy). The 95% joint confidence regions for each pair of binding 
parameters were generated by the MacELLIPSE program developed by the authors 
(Maggi and Rovati, 1993). Data obtained from kinetic experiments were  analysed by 
mean of the EXPFIT program (Guardabasso et al., 1988). 
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3. RESULTS 
 
3.1 - Effect of several steroidal compounds on the binding of opioid ligands to rat brain 
membrane preparations. 
Table 1 illustrates the effect of a 10 µM concentration of several physiological steroids, 
of three synthetic steroid antagonists (RU486, ZK98299 and tamoxifen), and of the 
steroid ester, 17α-hydroxy-progesterone caproate on the binding of labelled 
dihydromorphine [3H]dihydromorphine to µ-opioid receptors present in rat brain 
membrane preparations. First of all, it was evident that the two vehicles DMSO and 
ethanol, at the concentrations used to dissolve the various compounds, did not interfere 
with the binding of [3H]dihydromorphine to µ-opioid receptors. Among the natural 
steroids tested, only 17ß-estradiol and 17α-hydroxy-progesterone were partially able to 
inhibit the binding of [3H]dihydromorphine (41% and 33%, respectively). All other 
physiological steroids appeared to be devoid of any significant inhibitory activity 
(Table 1). Among the synthetic compounds tested, the progesterone antagonists, RU486 
and ZK98299, were able to inhibit almost completely (>90%) the specific binding of 
[3H]dihydromorphine to rat brain membrane preparations; while the estrogen 
antagonist ,tamoxifen (which does not possess a steroidal structure), was ineffective. 
Also, 17α-hydroxy-progesterone caproate, contrary to what was observed with 17α-
hydroxy-progesterone, was totally inactive (Table 1).  
Subsequent  experiments served to characterise the mode of action of the most effective 
progesterone antagonist, RU486. 
To rule out the possibility that the effects of the progesterone antagonists might be 
linked to the particular opioid ligand chosen, the action of RU486 was investigated on 
rat brain membrane preparations using as ligands either the µ-opioid receptor agonist, 
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[3H]DAGO, or the non-selective opioid receptor antagonist, [3H]diprenorphine. It is 
apparent from Table 2 that the competing effect of RU486 (10 µM) on the binding of 1 
nM [3H]DAGO was similar to that exerted on the binding of [3H]dihydromorphine. On 
the contrary, the specific binding of 0.5 nM [3H]diprenorphine was decreased by  only 
about 25% in the presence of RU486. 
Fig. 1 illustrates the competition curves for RU486, 17α-hydroxy-progesterone and 
17ß-estradiol on the binding of [3H]dihydromorphine to rat brain membrane 
preparation. These curves reveal that RU486 inhibited the binding of 
[3H]dihydromorphine in a dose-dependent manner, with a potency (expressed as IC50)  
of 0.50 µM. It was not possible to evaluate the IC50 of 17α-hydroxy-progesterone and 
of 17ß-estradiol. This was because it was difficult to reach the high concentrations of 
these steroids required for complete inhibition of [3H]dihydromorphine binding, due to 
their limited solubility in the incubation buffer.  
RU486 exerted an inhibitory effect on [3H]dihydromorphine binding also when tested 
in membrane preparations derived from mouse rather than from rat brain, and from the 
human neuroblastoma cell line, SH-SY5Y (Table 3). The IC50 of RU486 in these 
different preparations was of the same order of magnitude (Table 3).  
 
3.2 - Effect of RU486 on the binding characteristics of [3H]dihydromorphine to rat 
brain membrane preparations. 
3.2.1 - Saturation curves.  Analysis of saturation curves of the binding of 
[3H]dihydromorphine to rat brain membrane preparations, in the absence or in the 
presence of 5 µM RU486, showed that RU486 induces a significant decrease of the 
affinity of [3H]dihydromorphine (Kd values varying from 0.34 nM to 1.08 nM, P<0.05 
by F test performed with the program LIGAND), without any modification of the 
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maximal binding capacity (Bmax), suggesting a possible competitive effect of the 
steroid on the opioid receptor. This is seen in Fig. 2, where the results are presented as a 
log Kd-log Bmax plot obtained from the analysis of these curves; the ellipses represent 
the 95% joint confidence regions of the two binding parameters. 
3.2.2 - Kinetic studies. To further characterise the mode of action of RU486, its effects 
were studied on the rates of association and dissociation of [3H]dihydromorphine to rat 
brain membrane preparations. To this purpose, aliquots of membrane samples were 
incubated with [3H]dihydromorphine (1 nM), and the reaction was stopped at various 
times of incubation; this approach permits the determination of the rate constant of 
association (k+1) of [3H]dihydromorphine. In order to obtain the value for the rate 
constant of dissociation (k-1), some of the samples incubated, which had reached a 
stable binding equilibrium (at 60 min), were exposed to unlabeled dihydromorphine (1 
µM final concentration). The experiment was performed in the absence or in the 
presence of RU486 (5 µM). The results, shown in Fig. 3, indicate that RU486 induced a 
significant decrease of the association rate constant (k+1) of [3H]dihydromorphine 
(from 0.072 min-1 in control membranes to 0.002 min-1 in RU486-treated membranes, 
P<0.05), without significantly altering the dissociation rate constant (k-1; 0.030 min-1 
and 0.038 min-1, respectively).  
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In the binding experiments so far described, the steroids had been added to the 
membrane preparations simultaneously with the labelled ligands; it was then necessary 
to test the ability of RU486 to dissociate the complex, [3H]dihydromorphine-µ-
opioid receptors, when it was already formed. Membranes were incubated with 
[3H]dihydromorphine until binding equilibrium was reached; at this point unlabeled 
dihydromorphine (1 µM final concentration) or RU486 (10 µM) was added and the 
reaction was stopped at different times. Fig. 4 shows that, as expected, unlabeled 
dihydromorphine dissociates completely the [3H]dihydromorphine from its binding 
sites. On the contrary, the dose of RU486 that was able to inhibit almost completely the 
binding of [3H]dihydromorphine when added at the beginning of the incubation period 
dissociated only partially the [3H]dihydromorphine-µ-opioid receptor complex (max 
inhibition 40%), with a significantly slower rate of dissociation than unlabeled 
dihydromorphine (k-1= 0.0121 min-1 vs. 0.0556 min-1).  
3.2.3 - Effect of sodium ions. It is well known that the binding of opiate agonists to 
opioid receptors is influenced by monovalent ions. Opioid receptor agonists, in 
particular, show a reduced binding affinity to the µ-opioid receptor in the presence of 
sodium ions. Consequently, it was of interest to verify whether the decrease of affinity 
of [3H]dihydromorphine for the µ-opioid receptor induced by RU486 was due to 
mechanisms similar to those operating in the case of sodium ions. As expected, the 
addition of NaCl (100 mM) to the incubation buffer induced a six-fold decrease of the 
affinity of [3H]dihydromorphine for the µ-opioid receptors (Kd 0.17 nM for control and 
1.05 nM in the presence of NaCl) present in rat brain membrane preparations. Table 4 
shows that the inhibition exerted by a 10 µM concentration of RU486 on the binding of 
1 nM [3H]dihydromorphine to brain membrane preparation was significantly decreased 
in the presence of sodium ions. 
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3.3 - Evaluation of [3H]dihydromorphine binding and opioid-mediated inhibition of 
cyclic AMP accumulation in  SH-SY5Y neuroblastoma cells after RU486 treatment  
Further evaluation of the effects of RU486 on opioid µ-opioid receptors was performed 
on living cells in a defined in vitro system taking advantage of the availability of the 
human neuroblastoma cell line, SH-SY5Y, which is rich in µ-opioid receptors. In a first 
series of experiments, the binding characteristics of [3H]dihydromorphine were 
analysed in membrane preparations obtained from SH-SY5Y cells cultured for six days 
in the presence of 10 µM RU486. Five minutes before harvesting, RU486 (10 µM final 
concentration) was added to control untreated cells, to eliminate the possibility that the 
effects exerted by RU486 in the treated cells might be linked to the presence of a 
residual amount of the steroid, which could obviously alter the results of the receptor 
binding assay. All the cells were then processed, as described in Materials and 
Methods, to obtain membrane preparations that were washed extensively to remove any 
residual RU486.  
Fig. 4, which presents the 95% joint confidence ellipses of the binding parameters, 
shows that a 6-day treatment of SH-SY5Y cells with RU486 induced a significant 
decrease of the affinity of [3H]dihydromorphine for the µ-opioid receptor (Kd values: 
0.22 nM for control cells, and 6.59 nM for RU486-treated cells; P<0.05), but does not 
induce any significant change of the Bmax.  
It is well known that, in opioid responsive systems, opioid  receptor agonists (e.g., 
morphine) inhibit the accumulation of cyclic AMP induced by prostaglandin E1. In 
order to evaluate whether RU486 might influence a biochemical parameter associated 
with µ-opioid receptor function, the accumulation of cyclic AMP induced by 
prostaglandin E1 was evaluated in intact SH-SY5Y cells. In these experiments, the 
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basal content of intracellular cyclic AMP was 60 pmol/mg protein; this was increased 
by 183 % by the treatment with prostaglandin E1. The presence of 10 µM RU486 
(during the 15-min of incubation necessary to observe the prostaglandin E1 stimulation, 
or with chronic, six-day treatment) did not modify either the basal levels of intracellular 
cyclic AMP (data not shown) or the prostaglandin E1-stimulated levels of intracellular 
cyclic AMP (Table 5). In the 15-min experiments, RU486 was also unable to modify 
the inhibition of cyclic AMP accumulation induced by morphine in prostaglandin E1-
stimulated cells (Table 5). However, the chronic, 6-day treatment with RU486 
eliminated the inhibitory effect of morphine on the accumulation  of cyclic AMP 
induced by prostaglandin E1 (Table 5). 
 
4. DISCUSSION 
 
The present study analysed first the effects of different steroids on the in vitro binding  
of [3H]dihydromorphine to µ-opioid receptors present in rat brain membrane 
preparations. From the results obtained it appears that, among the twelve physiological 
steroids examined, only 17ß-estradiol and 17α-hydroxy-progesterone partially inhibited 
the binding of [3H]dihydromorphine.  The results also indicate that other naturally 
occurring steroids (e.g., corticosterone, testosterone, progesterone and some of their 
metabolites) do not interfere with the binding of [3H]dihydromorphine to brain µ-
opioid receptors. These observations are in partial agreement with those of a recent 
study by Schwarz and Pohl (1994), who reported that elevated concentrations of 17ß-
estradiol alter with similar potencies the binding of different opioids to the µ-, δ- and κ-
opioid receptors. In the same study, the IC50 of 17ß-estradiol was greater than 10µM 
(Schwarz and Pohl, 1994), i.e. close to that expected from the data presented here. In 
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agreement with the present data, it has also been found that testosterone, 
dihydrotestosterone and progesterone are practically ineffective to displace opioid 
ligands (Schwarz and Pohl, 1994). However, at variance with the results of Schwarz 
and Pohl (Schwarz and Pohl, 1994), in the present experiments it was found that 17α-
hydroxy-progesterone competes with [3H]dihydromorphine binding with a potency 
similar to that of 17ß-estradiol. The reasons for this small discrepancy are probably 
some methodological differences.  
The fact that high doses of a wide range of natural steroids and of their metabolites 
(with the exception of 17ß-estradiol and 17α-hydroxy-progesterone) do not directly 
modify the binding of opioid ligands to the µ-opioid receptors suggests that the effects 
observed after in vivo treatments with hormonal steroids on the binding characteristics 
of opioid receptors  (Dondi et al., 1992; Jacobson and Kalra, 1989; Maggi et al., 1989) 
are due to indirect mechanisms, for instance, modulation of the synthesis of the opioid 
receptors, or an effect on the opioid-producing neurons resulting in down- or up- 
regulation of the receptors because of the increased or decreased amounts of the 
endogenous ligand released. 
The results presented here have also shown that the progesterone antagonist, RU486, 
inhibits with a high potency (>90%) the binding of [3H]dihydromorphine to all the 
preparations containing the µ-opioid receptors studied (rat brain, mouse brain, 
neuroblastoma cell membrane preparations). The progesterone antagonist, ZK98299, 
which possesses a chemical structure similar to that of RU486 (Fig. 5), showed a 
similar inhibitory effect in the preparations in which it was studied. The observation 
that the competition of RU486 for [3H]dihydromorphine binding was evident in all 
situations examined rules out the possibility that the phenomenon observed might be 
linked only to a particular tissue preparation. In addition, RU486 was able to inhibit the 
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specific binding not only of [3H]dihydromorphine but also of another µ-opioid 
receptor agonist ([3H]DAGO) emphasising that this synthetic steroid is able to 
specifically affect the µ subtype of opioid receptors. This is also suggested by the fact 
that RU486 inhibited only partially (25%) the binding of the opioid non-selective 
antagonist [3H]diprenorphine which binds with similar affinities to µ, δ and κ opioid 
receptors (Leslie, 1987; Magnan et al., 1982; Paterson et al., 1983).  
From the results reported here, it appears that RU486 inhibits the binding of 
[3H]dihydromorphine in a dose-dependent fashion, with an IC50 ranging from 0.50 to 
0.85 µM for the different tissues or cell preparations used. These values are lower than 
those reported for the effect of other steroids on the σ and the muscarinic receptors 
(Klangkalya and Chan, 1988; Su et al., 1988). It is interesting that these values are 
similar to those found for the binding of some protein-linked steroids (e.g., bovine 
serum albumin-progesterone) to their putative membrane binding sites (0.1 µM)(Ke and 
Ramirez, 1990; Ramirez et al., 1990). The present results also indicate that the effect of 
RU486 on µ-opioid receptors results in a decrease of the affinity of opioid receptor 
agonists for their receptors, and that this decrease of affinity is secondary to a 
diminished association rate of the ligand to the µ-opioid receptors, rather than to an 
increase of its dissociation rate. The present observations support the view that steroids 
can also convert the µ-opioid receptors to a low affinity state, as has been reported for 
the effects exerted by some steroids on other neurotransmitter (e.g., the dopamine D2 
receptor), and peptide (e.g., the receptors for insulin and tumour necrosis factor) 
receptors (Cull, 1988; Kahn et al., 1978; Levesque and Di Paolo, 1988). The decrease 
of the affinity of [3H]dihydromorphine, observed in the present study after treatment 
with RU486, might suggest competitive antagonism of the steroid of µ-opioid binding 
sites. However, RU486, at the dose that almost completely inhibited 
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[3H]dihydromorphine binding when added simultaneously with the labelled ligand, was 
much less effective to displace [3H]dihydromorphine when the ligand-receptor 
complex is already formed. This seems to rule out the possibility of a simple 
competitive interaction of RU486 on the µ-opioid receptor.  
It has been reported that steroids may interact with cell membrane structures; it has also 
been proposed that the anchoring of steroids at membrane interfaces may produce 
membrane perturbation (Makriyannis et al., 1990). In addition, it has been found that 
exposure of rat brain membranes to highly hydrophobic molecules (e.g., fatty acids) 
may result in alteration of membrane fluidity, which may modify the binding 
characteristics of opioid ligands (Remmers et al., 1990). These facts, suggest the 
hypothesis that, because of its hydrophobic nature, RU486 might interfere with the 
binding of [3H]dihydromorphine by an interaction with membrane constituents. 
However, it is difficult to ascribe the potent action of RU486 on µ-opioid binding only 
to the hydrophobicity linked to its steroidal structure, since none of the other steroids 
tested showed similar activity. This hypothesis is also supported by the observation that 
17α-hydroxy-progesterone becomes ineffective when conjugated with a caproic fatty 
acid residue. It must also be considered that, RU486 and ZK98299, which are both 
capable of inhibiting almost completely the binding of [3H]dihydromorphine, have a 
strictly similar chemical structure, characterised by the addition of a 
dimethylaminophenyl group in position 11ß (Fig. 5). It is probable that the inhibitory 
effect on [3H]dihydromorphine binding shown by these two steroids might  be due to 
this particular functional group.  
Opioid receptors are members of a superfamily of membrane-linked binding sites 
coupled to GTP-binding proteins (G proteins) (Leslie, 1987). The binding of opioid 
receptor agonists (but not of opioid receptor antagonists) to opioid receptors is 
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decreased in the presence of sodium ions (Pert and Snyder, 1974; Puttfarcken et al., 
1986), which are fundamental to the coupling of opioid receptors to G proteins. The 
apparent decrease of the affinity observed in the presence of sodium seems to be  
secondary to conformational changes of the receptor, which also modify its coupling to 
G proteins (Law et al., 1983). In the present work, it was found that the inhibitory effect 
of RU486 on the binding of dihydromorphine to µ-opioid receptors was significantly 
decreased in the presence of NaCl, a result which suggests that the effect of RU486 is, 
at least in part, mediated by some mechanisms similar to those which operate in the 
case of sodium ions. This hypothesis agrees with the evidence now reported, showing 
the decreased ability of RU486 to inhibit the binding of the non-selective antagonist 
[3H]diprenorphine; as previously mentioned, the binding of opioid receptor antagonists 
is insensitive to the low affinity state of the receptors induced by sodium ions (Pert and 
Snyder, 1974; Puttfarcken et al., 1986). These considerations lead to the speculation 
that RU486 may interact with membrane structures involved in the control of the 
coupling of opioid receptors with G proteins. This hypothesis is not overly speculative, 
considering the recent findings showing that some natural steroids may interact with 
other GTP-binding protein coupled receptors (Minami et al., 1990; Petitti and Etgen, 
1992; Wehling, 1994).  
The results of the experiments on intact living neuroblastoma cells have shown that a 
chronic, six-day, treatment with RU486 induces a decrease of the affinity of 
[3H]dihydromorphine to opioid receptors and a block of the inhibitory effect of 
morphine on the accumulation of cyclic AMP induced by prostaglandin E1. In the same 
experiment it was found that acute treatment  (15 min) with RU486 was unable to 
modify the inhibitory effect of morphine on prostaglandin E1-induced cyclic AMP 
accumulation. This is not surprising considering the decreased effect of RU486 on 
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[3H]dihydromorphine binding in the presence of sodium, an ion that is obviously 
present in the incubation buffer.  
Several in vitro and in vivo aspects of the biological profile of RU486 previously 
reported, cannot be explained by its antiprogesterone activity; some might be linked to 
the effects on the opioid system reported here. For instance, it has been shown that 
RU486 may decrease the proliferation of immune cells in vitro even in the absence of 
cortisol or progesterone  (Bradley et al., 1989; Monterroso and Hansen, 1993); it is well 
known that opioids may induce immunosuppression (Donahoe and Falek, 1988). It has 
also been reported that RU486 is able to block pituitary FSH secretion through a  
mechanism that does not involve progesterone and/or its receptors (Knox et al., 1993); 
opioids are known to exert inhibitory control on pituitary gonadotropin secretion. There 
are some data which support the biological relevance of the findings reported here. It 
has been found that RU486 partially blocks the increase of methallothionein occurring 
in the rat liver under the influence of morphine (Hidalgo et al., 1991). Moreover, recent 
results from this laboratory have shown that two-day treatment of mice with RU486 
reduces the increase in pain threshold induced by morphine, as measured by the hot 
plate test; this effect does not appear to be antagonised by either progesterone or 
dexamethasone (Bianchi et al., submitted). 
One usual criticism of studies showing effects of steroids on the binding characteristics 
of neurotransmitter and peptide receptors is that physiological steroids cannot reach 
adequate concentrations in biological fluids to interact with binding sites characterised 
by an affinity in the micromolar range (Schwarz et al., 1989; Schwarz and Pohl, 1994).  
However, it is relevant to mention that an almost 10 µM concentration of RU486 is 
achieved in biological fluids of women under abortifacient treatment (Liu et al., 1988). 
It is probable that, at these concentrations, the steroid influences peripheral µ-opioid 
19 
receptors. It is known that RU486 does not easily cross the blood-brain barrier. 
However, it is possible that the steroid, at the highest in vivo concentrations, might 
penetrate in the brain areas where the blood-brain barrier does not exist (median 
eminence, circumventricular organs, etc.). In conclusion, the present data show that 
physiological steroids (e.g., 17ß-estradiol and 17α-hydroxy-progesterone) as well as 
synthetic progesterone antagonists may interfere with the binding of specific ligands to 
the µ-opioid receptor. These findings support the hypothesis that, at least in the nervous 
cells, steroids may act through non-genomic mechanisms also.  
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FIGURE LEGENDS  
 
FIG. 1 
Dose-dependent inhibition of [3H]dihydromorphine binding to rat brain membrane 
preparations by unlabeled dihydromorphine (closed circles), RU486 (open circles), 
17β-estradiol (triangles) and 17α-hydroxyprogesterone (squares). Incubations of 
membrane preparations were started by simultaneous addition of the labeled ligand and 
the competitors. 
 
FIG. 2 
95% joint confidence regions of the binding parameters of [3H]dihydromorphine to µ 
opioid receptors present in rat brain membrane preparations obtained from saturation 
curves made in the absence (open ellipse) or in the presence (shaded ellipse) of a 5 µM 
concentration of RU486.  
 
FIG. 3 
Association and dissociation curves of the [3H]dihydromorphine binding to rat brain 
membrane preparations, in the absence (close circles) or presence (open circles) of 5µM 
RU486. Aliquots of membrane preparations were incubated  in the presence of 1 nM 
[3H]dihydromorphine and the incubation was stopped at different times until a stable 
equilibrium was reached. Some of the incubated membranes were left to reach 
equilibrium and the [3H]dihydromorphine bound to membranes was dissociated by the 
addition of 1 µM unlabeled dihydromorphine (arrow). INSET: dissociation of 
[3H]dihydromorphine bound to rat brain membrane preparations by unlabeled 
dihydromorphine and RU486 (inset). Aliquots of membrane preparations were 
incubated  in presence of 1 nM [3H]dihydromorphine until equilibrium was reached (60 
29 
min). The [3H]dihydromorphine bound to membranes was then displaced by unlabeled 
dihydromorphine (1µM, closed circles) or RU486 (10 µM, open circles). 
 
FIG. 4 
95% joint confidence regions of the binding parameters of [3H]dihydromorphine to mu 
opioid receptors present in SH-SY5Y human neuroblastoma cells after a six-day 
treatment with RU486. The cells were maintained for six days in the culture medium in 
the absence (open ellipse) or in the presence of a 10 µM concentration of RU486 
(shaded ellipse). The binding characteristics of [3H]dihydromorphine to mu opioid 
receptors were then evaluated on SH-SY5Y membrane preparations as described in 
Materials and Methods. 
 
FIG. 5 Structure of progesterone antagonists RU486 and ZK98299. 
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TABLES AND FIGURES 
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Table 1  
Effect of the "in vitro" addition of steroid hormones 
and synthetic analogs on the specific binding of 
[3H]dihydromorphine to rat brain membrane preparations. 
 
Compounds [3H]DHM 
specific 
binding 
(% of control) 
CV 
(%) 
Ethanol 1%  93.1 3.4 
DMSO 1%  98.1 2.0 
corticosterone  97.6 1.2 
progesterone  95.9 0.6 
5α-pregnane-3,20-dione (DHP)  94.3 4.6 
5α-pregnane-3α-ol-20-one (THP)  83.1 8.6 
5α-pregnane-3ß-ol-20-one  90.4 1.0 
5α-pregnane-3α,20α-diol  95.3 3.8 
5ß-pregnane-3,20-dione  97.5 1.8 
17α-hydroxy-progesterone   66.8a 5.0 
17α-hydroxy-progesterone caproate 105.0 3.8 
RU486    5.6a 3.4 
ZK98299    8.4a 2.4 
Testosterone  85.9 7.4 
5α-androstan-17ß-ol-3-one(DHT)  87.1 8.8 
Androsten-3ß,17ß-diol  87.5 6.0 
17ß-estradiol   59.2a 4.0 
Tamoxifen 
 
 75.7 4.8 
32 
The steroids and tamoxifen were used at 10 µM 
concentration. 
a Significant (P<0.05) vs. DMSO or Ethanol 
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Table 2  
Effect of the "in vitro" addition of RU486 (10 µM ) 
on the specific binding of the µ-opioid receptor 
agonist, [3H]DAGO, and the opioid receptor 
antagonist, [3H]diprenorphine, to rat brain 
membrane preparations. 
 
Ligand specific binding 
(% of control) 
 
DAGO   8.8a ± 0.2 
diprenorphine 
 
 73.2a ± 4.7 
 
Values are means ± S.D. of quadruplicate 
determinations obtained from two independent 
experiments. 
a Significant (P<0.05) vs. control samples 
containing 1% DMSO. 
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Table 3  
Inhibitory effect of RU486 (10 µM ) on the binding 
of [3H]dihydromorphine to membrane preparations 
obtained from rat brain, mouse brain and SH-SY5Y 
human neuroblastoma cells. 
 
Tissue 
 
IC50 (µM) CV(%) 
rat brain  0.5  5.4 
mouse brain  0.76  6.2 
SH-SY5Y cells 
 
 1.73  12.5 
Competition curves were analysed with the 
program, ALLFIT. CV is the coefficient of 
variation of the estimated IC50 value. 
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Table 4 
Effect of RU486 (10 µM) on [3H]dihydromorphine 
binding to rat brain membrane preparations in the 
presence or in the absence of NaCl. 
 
Group [3H]DHM specific 
binding 
(% of control) 
 
RU486   5.4  ± 0.2 
RU486 + 100 mM NaCl 
 
 52.3a ± 5.8 
Values are means ± S.D. of quadruplicate 
determinations obtained from two independent 
experiments. 
a Significant (P>0.05) vs. RU486 
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Table 5  
Effect of the "in vitro" addition of RU486 (10 µM) 
on the morphine inhibition of prostaglandin E1-
induced cyclic AMP accumulation in intact SH-SY5Y 
human neuroblastoma cells. 
 
Treatments cyclic AMP 
accumulation 
(% of basal 
levels) 
 
inhibitory 
effect of 
morphine 
(%) 
PGE1+vehicle     183 ± 0.9  
PGE1+vehicle+morphine     137 ± 2.1a - 25 
15 min   
PGE1+RU486     182 ± 1.8  
PGE1+RU486+morphine     138 ± 3.2a - 24 
6 days   
PGE1+RU486     180 ± 1.3  
PGE1+RU486+morphine 
 
    182 ± 0.8   - 1 
Values are means ± S.D. of quadruplicate 
determinations obtained from two independent 
experiments.  
a Significant (P<0.05) vs. prostaglandin E1-
stimulated cells. 
